Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • MedXY story
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • MedXY story
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • KRASG12C
Adagrasib vs Docetaxel in KRASG12C-Mutated NSCLC: New Hope from KRYSTAL-12 Phase 3 Trial
Posted inClinical Updates Wellness & Lifestyle

Adagrasib vs Docetaxel in KRASG12C-Mutated NSCLC: New Hope from KRYSTAL-12 Phase 3 Trial

Posted by By MedXY 08/15/2025
The KRYSTAL-12 trial demonstrated that adagrasib significantly improves progression-free survival compared to docetaxel in previously treated KRASG12C-mutated advanced NSCLC, with manageable safety profiles.
Read More
  • How to Improve the Quality of Your Sex Life: 6 Methods and 8 Tips for Passionate Intimacy
  • Unveiling Surprising Insights into Sexual Health: Facts Everyone Should Know
  • Healthy Eating for the Planet: Linking Sustainable Diets with Reduced Cardiovascular Risk and Longevity
  • Adagrasib vs Docetaxel in KRASG12C-Mutated NSCLC: New Hope from KRYSTAL-12 Phase 3 Trial
  • Long-term Safety and Efficacy of Rabies Monoclonal Antibody and Vaccine for Post-Exposure Prophylaxis: Insights from a Phase 4 Trial in India
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

2型糖尿病 aging AI Alzheimer's disease artificial intelligence blood pressure breast cancer cardiovascular health cardiovascular risk clinical trial clinical trials COPD Dementia diabetes diet exercise health healthcare heart failure Hypertension immunotherapy ketogenic diet lifestyle longevity MASLD mental health NAFLD nutrition obesity phòng ngừa Pregnancy prevention public health randomized controlled trial randomized trial sexual health sleep stroke sức khỏe treatment type 2 diabetes weight loss wellness women's health 糖尿病

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top